Wall Street loves a good upgrade, especially when the stock has already doubled and the analyst can explain why everyone should have owned it six months ago.

One place I look for ideas is the investment portfolios of companies that already dominate their industries.

NVIDIA understands what it takes to build artificial intelligence infrastructure. Merck employs scientists who spend their careers separating promising medical research from expensive nonsense.

When one of these companies puts money into a smaller public business, I want to know why.

That does not mean I automatically buy the stock.

Large corporations make mistakes. They can simply afford larger ones than the rest of us.

A famous shareholder will not repair a weak balance sheet, rescue a bad business, or turn an absurd price into a bargain.

Corporate ownership gives us a clue.

It tells us that people with industry knowledge, technical expertise, commercial relationships, and plenty of money found something worth examining.

The clue becomes more useful when the corporate investor is also a customer, supplier, development partner, or source of long-term purchase commitments.

This fits nicely with the way we invest at Alpha Buying.

We can let the giants do some of the scouting and spend the first dollars.

We still run every candidate through our own work on credit, valuation, fundamental momentum, and price trend.

The latest portfolios of NVIDIA and Merck point us toward five companies worth examining.

NVIDIA owns Coherent and CoreWeave.

Merck owns Alector, Entrada Therapeutics, and Eikon Therapeutics.

None of them gets a free pass.

Each one, however, tells us where a dominant company sees demand, scarcity, or strategic value developing.

Let the Giants Do Some of the Scouting

The biggest companies in an industry often have a view of trouble and opportunity that the rest of the market does not.

They know where capacity is getting tight, which technologies are improving, what customers are requesting, and which smaller businesses own something that would be difficult or expensive to build from scratch.

They can also perform due diligence that individual investors cannot hope to match.

NVIDIA can evaluate an artificial intelligence infrastructure company while supplying the chips that make the whole operation possible.

Merck can put scientists, regulatory specialists, and commercial executives in a room before investing in a drug platform.

The check may be the least interesting part of the deal.

A strategic investor can bring a large customer, technical help, manufacturing expertise, credibility with lenders, and easier access to future financing.

The relationship may eventually lead to a licensing agreement, a larger commercial partnership, or an acquisition.

There is a less pleasant side to these arrangements.

The giant company may have all the bargaining power. The smaller business can become dependent on one customer, one supplier, or one source of capital.

Early shareholders may spend years financing a wonderful technology without ever seeing wonderful returns.

That is why I want to know whether the corporate relationship improves the smaller company’s chance of building a durable and profitable business.

The name on the shareholder list is interesting.

The economics of the relationship are what matter.

NVIDIA’s AI Infrastructure Bets

NVIDIA’s holdings offer a useful tour of the infrastructure surrounding the artificial intelligence boom.

Coherent and CoreWeave address different bottlenecks in the same buildout.

One moves the data.

The other rents the computing power.

Coherent (COHR): The Data Still Has to Move

Coherent may be the less glamorous of the two ideas.

I consider that a compliment.

Some of the best investments begin with equipment that nobody wants to discuss at a cocktail party.

Artificial intelligence data centers need more than processors.

Thousands of chips must exchange enormous amounts of information at very high speed without melting the building or bankrupting the owner through the electric bill.

That requires lasers, transceivers, optical components, and advanced networking technology.

The processor gets the magazine cover.

Coherent helps move the data that makes the processor useful.

NVIDIA made its interest clear in March.

Coherent issued approximately 7.8 million shares to NVIDIA at $256.80 per share and raised $2 billion.

The two companies also signed a multiyear strategic agreement covering advanced optics and next-generation artificial intelligence infrastructure.

The deal includes purchase commitments and access to additional Coherent product families related to advanced networking and co-packaged optics.

This goes well beyond NVIDIA buying a few shares and issuing the usual congratulatory press release.

NVIDIA is helping secure technology and manufacturing capacity that it expects to need.

Artificial intelligence clusters keep getting larger and denser.

More data must move inside each data center and between facilities. Copper connections eventually run into limits involving speed, distance, heat, and electricity use.

Optical technology becomes more important as those limits get tighter.

Coherent also sells into communications, industrial equipment, electronics, and specialized materials.

That broader business mix gives the company other sources of revenue when one market slows.

It also means COHR is not a pure artificial intelligence bet, which may disappoint investors who insist that every company presentation contain the maximum possible number of robots and glowing blue brains.

The risks are real.

Coherent operates in cyclical markets, faces strong competitors, and must spend heavily to expand advanced manufacturing.

Customers can postpone orders. New technology can require more investment than expected. A rich valuation can punish shareholders when growth merely slows instead of collapsing.

NVIDIA’s $2 billion investment does not make any of that disappear.

It does tell us that the most important supplier in artificial intelligence computing views Coherent as a serious partner, not an interchangeable vendor.

That is enough to put COHR near the top of the research list.

CoreWeave (CRWV): Enormous Demand and an Enormous Bill

CoreWeave is closer to the center of the artificial intelligence spending frenzy.

The company operates cloud infrastructure built for demanding computing workloads.

It buys large quantities of NVIDIA processors, installs them in data centers, and rents the computing capacity to customers building and operating artificial intelligence systems.

NVIDIA owned more than 47 million CoreWeave shares at June 30.

The position was worth roughly $4.7 billion when the filing was prepared.

CoreWeave reported approximately $104 billion of revenue backlog at the end of the second quarter.

It then added more than $25 billion of customer commitments early in the third quarter.

Finding demand does not appear to be keeping management awake at night.

Paying for everything required to satisfy that demand probably is.

CoreWeave must secure electricity, build or lease data centers, buy extremely expensive equipment, and finance expansion before much of the contracted revenue arrives.

A small number of customers account for a large portion of the business.

Huge contracts make the backlog look magnificent, but customer concentration can hurt if one buyer changes its plans or uses its size to demand better terms.

NVIDIA’s ownership offers powerful technical and commercial validation.

The chipmaker has a better view than almost anyone of CoreWeave’s ability to deploy the hardware and operate the infrastructure.

NVIDIA also benefits every time CoreWeave expands because a new facility usually creates another large order for NVIDIA products.

That last point deserves some attention.

NVIDIA can make money selling processors even if CoreWeave shareholders eventually discover that cloud infrastructure earns disappointing returns on capital.

The supplier and the common shareholder benefit from the same expansion, but they are not making the same investment.

CoreWeave may still become one of the major winners of the artificial intelligence boom.

Its backlog and access to scarce computing capacity create the possibility of extraordinary growth.

Debt, dilution, capital spending, and customer concentration create the possibility of an extraordinary headache.

COHR and CRWV give us two different ways to approach the same trend.

Coherent is the picks-and-shovels supplier moving data through the system.

CoreWeave is the faster-growing operator renting the computing power.

The first may appeal to investors who want somewhat steadier economics.

The second offers more growth along with much more financing and execution risk.

Merck Shops Outside Its Own Laboratories

Large drug companies have no choice but to search outside their walls.

Patents expire. Trials fail. Important discoveries often begin at small biotechnology companies.

Even the best internal research organization cannot invent everything it will need for the next decade.

Merck owns shares of Alector, Entrada Therapeutics, and Eikon Therapeutics.

The three companies are working on different diseases with different technologies at different stages of development.

Treating them as interchangeable biotechnology lottery tickets would miss the point.

I prefer to think of the group as a portfolio of scientific experiments.

Biotechnology outcomes can be brutally binary.

Several carefully selected positions make more sense than betting everything on one trial result and spending the night before the announcement pretending to sleep.

Alector (ALEC): Picking Through the Wreckage

Alector develops treatments for neurodegenerative diseases using immunology and genetic research.

Merck owned approximately 3.5 million shares at June 30.

ALEC is the contrarian name in this group because shareholders have already experienced the less entertaining side of biotechnology.

Alector’s latozinemab program failed a Phase 3 trial.

The company terminated another program after a Phase 2 failure.

Those disappointments forced management to reset the pipeline and the strategy.

The remaining case for the stock rests on Alector’s research platform, newer programs, and technology designed to carry medicines across the blood-brain barrier.

The blood-brain barrier is one of the basic problems in treating neurological disease.

A promising drug has limited value if it cannot reach the tissue it is supposed to treat.

Alector’s transport technology could be worth a great deal if it can move therapeutic molecules into the brain safely and consistently.

The company reported $206.5 million in cash and investments at the end of the first quarter.

Management expected that money to fund operations through at least 2027.

That buys time to advance the remaining work, although it does not rule out another capital raise later.

Merck’s ownership suggests that sophisticated pharmaceutical investors still see something worth pursuing in Alector’s platform or science.

The failed trials provide an equally useful reminder that interesting biology is not the same thing as an approved drug.

ALEC is the highest-risk turnaround of the five stocks in this article.

It could offer considerable upside if the market has assigned little value to technology that eventually produces a successful program or attracts a partner.

It could also remind us why small biotechnology positions should remain small.

Position size matters much more than enthusiasm here.

Entrada Therapeutics (TRDA): Getting Medicine Inside the Cell

Entrada Therapeutics is developing medicines intended to reach targets inside cells.

Its programs focus on serious diseases that have been difficult to address with conventional treatments.

The clinical pipeline includes potential treatments for Duchenne muscular dystrophy, a devastating genetic muscle disease.

Entrada also has a partnership with Vertex Pharmaceuticals involving a potential treatment for myotonic dystrophy type 1.

Another program targets Usher syndrome, a genetic disorder that can cause hearing and vision loss.

Merck owned approximately 1.7 million Entrada shares at June 30.

The position is modest, but the attraction is understandable.

A successful delivery technology can support more than one drug.

If the platform can carry therapeutic cargo into cells safely and effectively, Entrada could have several shots on goal across multiple diseases.

Entrada ended 2025 with approximately $296 million in cash and investments.

Management expected its resources to support operations into the third quarter of 2027.

Trial progress, partner activity, and decisions about which programs move forward will determine how long the money actually lasts.

The Vertex partnership adds another informed observer to the shareholder story.

Vertex examined the technology closely enough to commit to a program.

Merck’s ownership suggests that its investment team also found the platform worth following.

The clinical data will settle the argument.

The delivery system must work repeatedly and safely.

Encouraging results from an early trial can disappear when more patients are treated.

Delays can consume cash with nothing to show for it except another presentation explaining why the next update will be the important one.

TRDA has a broader scientific case than a company built around one drug.

Shareholders are betting on the individual programs and the delivery platform behind them.

Eikon Therapeutics (EIKN): More Cash and Later-Stage Programs

Eikon Therapeutics appears to be the most mature and best-funded of Merck’s three biotechnology holdings discussed here.

Merck owned approximately 1.7 million shares at June 30.

Eikon was founded around imaging technology that allows researchers to observe proteins moving inside living cells.

The company has used that scientific base to assemble a pipeline of cancer treatments.

Its leading program, EIK1001, is in registrational studies for melanoma and lung cancer.

Researchers are also studying the drug with pembrolizumab, the active ingredient in Merck’s Keytruda.

Other Eikon programs target PARP1, WRN, and the androgen receptor.

Eikon reported $531.2 million in cash and investments at the end of the second quarter.

That gives it more financial room than many development-stage biotechnology companies.

Late-stage oncology trials are still quite capable of consuming even a large pile of cash.

The Merck connections go beyond the investment.

Former Merck research leader Roger Perlmutter leads Eikon. Former Merck chief executive Kenneth Frazier has also served in company leadership.

Those relationships do not make the drugs work, but they help explain why Merck would have an unusually good understanding of the people, the science, and the development plan.

Cancer research remains intensely competitive.

Combination studies can be hard to interpret, and an exciting response rate does not always produce longer survival or regulatory approval.

EIKN offers the most developed story of the three Merck holdings.

ALEC is the battered recovery candidate.

TRDA offers a delivery platform with several possible applications.

EIKN brings later-stage programs, substantial cash, and a management team with deep Merck ties.

The question is whether those advantages can produce a commercial oncology business.

A Famous Shareholder Is Not Enough

Corporate ownership is an additional clue.

It does not replace the four pillars we use to judge every investment.

Credit comes first.

A company needs enough cash to reach its next important milestone. We need to know how much debt must be refinanced and whether growth will require repeated stock offerings.

CoreWeave faces enormous capital requirements.

The biotechnology companies must finance years of research before product revenue becomes possible.

Valuation comes next.

What has to go right to justify the current price?

A company can have a world-class partner and still be a terrible purchase at the wrong valuation.

Great businesses bought at ridiculous prices have a disturbing tendency to become mediocre investments.

Fundamental momentum tells us whether the opportunity is improving.

For Coherent, I want to see orders, margins, capacity, and cash flow moving in the right direction.

CoreWeave must convert backlog into revenue without allowing financing costs to consume the economics.

The biotechnology companies need clinical data, regulatory progress, partnerships, and enough cash to reach the next meaningful result.

Price trend is the fourth pillar.

Markets often recognize a change before it becomes obvious in the financial statements.

I prefer improving fundamentals accompanied by positive intermediate- and long-term trends.

A falling stock may be cheap.

It may also be warning us about financing stress, execution problems, or expectations that remain far too high.

The corporate relationship adds another set of questions.

Is the investor also a customer, supplier, or development partner?

Is the position large enough to matter?

Does the smaller company have other customers and financing choices?

Are the commercial terms attractive for both parties?

Could the arrangement lead to more products, distribution, licensing, or acquisition interest?

One question matters more than all the others:

Can the smaller company succeed if the corporate investor never writes another check?

If the answer is no, we are not looking at strategic validation.

We are looking at dependency.

Follow the Money, Then Do the Work

NVIDIA and Merck have industry access, technical expertise, and due diligence resources that individual investors cannot reproduce.

Their portfolios can steer us toward bottlenecks, emerging technologies, and smaller businesses that deserve a closer look.

COHR and CRWV offer two very different ways to participate in the artificial intelligence infrastructure buildout.

ALEC, TRDA, and EIKN cover a range of biotechnology opportunities, from a battered platform trying to recover to later-stage cancer programs.

Every company on the list carries serious risk.

Financing, valuation, competition, regulation, execution, and scientific failure are not minor details tucked into the back of the prospectus.

They will decide whether these stocks become winners.

That uncertainty is why the approach can be useful.

We are not searching for obvious perfection after every portfolio manager on Wall Street has already discovered it.

We are looking for situations where strategic validation, improving fundamentals, financial staying power, and a favorable price trend begin to come together before the opportunity becomes obvious.

Let the industry giants identify the bottlenecks and examine the technology.

Let them spend the first dollars.

Our job is to decide whether the stock offers enough upside to justify the risk.

That is a much better use of corporate portfolio disclosures than admiring the winners after they have already risen 500%.